Sakai Chemical Industry (4078) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for the first three quarters showed higher operating income despite lower revenue. Improvements in the cost structure and product mix lifted core business profitability, while net income declined due to a substantial impairment loss. Revenue was ¥613.7B (-3.5% YoY), Operating Income was ¥53.7B (+14.7%), Ordinary Income was ¥54.8B (+10.2%), and Net Income attributable to owners of the parent was ¥29.0B (-22.2%). The primary factor behind the decline in net income was the ¥24.3B impairment loss recognized in the Cosmetics Materials segment, which should be evaluated separately from the improvement at the operating level.

Factors Affecting Performance

【Revenue】Revenue was ¥613.7B, down 3.5% YoY. Although Electronic Materials (+14.8%) and Organic Chemicals (+17.4%) contributed to higher revenue, their gains were more than offset by declines in Titanium Oxide & Zinc Products (-23.7%), Resin Additives (-12.8%), and Cosmetics Materials (-37.8%), resulting in an overall decrease in revenue.

【Profitability】Operating Income was ¥53.7B (+14.7% YoY), and the operating margin improved to 8.7% from approximately 7.4% in the previous year. Growth in high-margin segments such as Catalysts (profit +232.5%), Organic Chemicals (+45.1%), and Electronic Materials (+25.0%) offset declines in profitability in Titanium Oxide & Zinc Products and Cosmetics Materials. Ordinary Income also maintained its upward trend at ¥54.8B (+10.2% YoY); however, following the recognition of ¥14.2B in gains on the sale of fixed assets and ¥25.6B in extraordinary losses, including a ¥24.3B impairment loss, Net Income declined to ¥29.0B (-22.2% YoY). In conclusion, on a core business basis, the Company recorded lower revenue and higher profit—not lower revenue and lower profit—at the operating and ordinary income levels. The decline in net income represents a temporary divergence caused by extraordinary income and expenses.

Segment Analysis

The largest contributor to profit was Electronic Materials, which achieved both growth and improved profitability, with revenue of ¥86.7B (+14.8% YoY), Operating Income of ¥14.4B (+25.0%), and a profit margin of 16.6%. Catalysts remained approximately flat in revenue at ¥24.4B, but profit increased to ¥5.4B (+232.5%), with profitability improving substantially to a high margin of 22.2%. Inorganic Materials also maintained a high profit margin of 22.5%. Meanwhile, Cosmetics Materials fell into an operating loss of ¥2.2B, compared with a profit of ¥1.1B in the previous year, on revenue of ¥11.2B (-37.8% YoY), and recorded a ¥24.1B impairment loss. Titanium Oxide & Zinc Products (revenue -23.7%, profit -10.9%) and Resin Additives (revenue -12.8%, profit -25.2%) were also affected by market conditions and lower volumes. After deducting Company-wide expenses of ¥18.3B from the total profit of the reported segments of ¥72.0B, consolidated Operating Income was ¥53.7B.

Key Financial Indicators

【Profitability】The operating margin was 8.7%, improving from approximately 7.4% in the previous year, while the net profit margin was 4.7%, declining from approximately 5.9% in the previous year. This clearly indicates that improvements at the operating level were not reflected in net income. ROE was 3.8% on a cumulative basis, or approximately 4.9% on an annualized basis. The low net profit margin and low asset turnover are weighing on ROE. 【Cash Quality】Accounts receivable of ¥228.9B and inventories of ¥169.3B indicate a substantial investment in working capital, suggesting slow turnover of inventory and accounts receivable. 【Investment Efficiency】Property, plant and equipment of ¥432.2B accounted for 36.8% of total assets, indicating an asset structure that is capital intensive. Meanwhile, goodwill of ¥6.9B represented only 0.9% of net assets, indicating a low degree of dependence on M&A. 【Financial Soundness】The Equity Ratio was 66.5%. With current assets of ¥654.2B versus current liabilities of ¥253.9B, the Company maintains substantial liquidity. Operating Income coverage of interest payments of ¥1.2B was approximately 44 times, indicating extremely strong interest-servicing capacity.

Cash Flow Analysis

As a cash flow statement has not been disclosed, fund movements are analyzed based on changes in the balance sheet. Cash and deposits were ¥114.9B, down from ¥161.8B in the same period of the previous year, and remained only slightly above short-term borrowings of ¥105.8B. Accounts receivable of ¥228.9B and inventories of ¥169.3B were approximately flat or trending upward from the previous year, suggesting that funds tied up in working capital may be constraining financial flexibility. Interest-bearing debt totaled approximately ¥155.8B on a combined short- and long-term basis, slightly lower than in the previous year, suggesting that financing cash flow was a net outflow. Construction in progress related to capital expenditures was ¥34.9B, down from ¥50.4B in the previous year, indicating that the scale of investment was somewhat restrained. Overall, cash on hand has not accumulated to the same extent as the increase in operating profit, and reducing working capital will be key to improving future cash generation.

Quality of Earnings

Ordinary Income increased 10.2% YoY to ¥54.8B, confirming improvement derived from the core business; however, extraordinary income and expenses had a significant impact in the transition to Net Income of ¥29.0B. Against extraordinary income of ¥14.2B, including ¥14.2B in gains on the sale of fixed assets, the Company recorded extraordinary losses of ¥25.6B, primarily comprising a ¥24.3B impairment loss in the Cosmetics Materials segment, resulting in a net loss factor of ¥11.4B. The total impact of extraordinary income and expenses was very large relative to net income, and it would not be appropriate to use the current level of net income as-is as an indicator of recurring earnings power. Non-operating income totaled ¥4.1B, including dividend income of ¥2.1B and foreign exchange gains of ¥0.4B, against non-operating expenses of ¥3.0B, including interest payments of ¥1.2B. At approximately 0.7% of revenue, these items were not large enough to materially distort the evaluation of the core business. Overall, the increase in Operating Income and Ordinary Income is qualitatively positive, but Net Income was significantly affected by a temporary impairment loss.

Earnings Forecasts and Guidance

Progress against the full-year forecast was 71.4% for revenue, 82.6% for Operating Income, 84.3% for Ordinary Income, and 96.7% for Net Income attributable to owners of the parent. Revenue progress was slightly below the standard 75%, requiring revenue of ¥246.3B to be recorded in Q4. In contrast, profit progress was generally high: against the full-year Operating Income forecast of ¥65.0B, the remaining amount required was only ¥11.3B, while against the Ordinary Income forecast of ¥65.0B, the remaining amount was ¥10.2B. Net Income progress was particularly high because the remaining ¥1.0B required to reach the full-year forecast of ¥30.0B, which already incorporates the impairment burden, is achievable. The Company’s plan assumes a recovery in revenue in Q4 while maintaining a conservative structure on the profit side.

Shareholder Returns

The Q2 dividend was ¥65.00 per share, and the full-year forecast dividend is ¥145.00, including an assumed year-end dividend of ¥80.00. Based on forecast Net Income attributable to owners of the parent of ¥30.0B and annual total dividends of approximately ¥22.8B, calculated as the average number of shares outstanding during the period of 15,690 thousand shares × ¥145, the Payout Ratio is approximately 75.8%, above the general benchmark of 60%. As the current year is one in which net income was reduced by an impairment loss, the high Payout Ratio is considered to reflect both the decline in earnings power and the priority assigned to capital policy. The Equity Ratio of 66.5% and high current ratio support the safety margin for dividends; however, amid the noted accumulation of working capital, the effective sustainability of the dividend will depend on future trends in Operating Cash Flow.

Risk Factors

1. Deterioration in the profitability of the Cosmetics Materials Business: Revenue declined 37.8% from the same period of the previous year to ¥11.2B, the business fell into an operating loss of ¥2.2B, and an impairment loss of ¥24.3B was recorded. If the recovery in demand and competitiveness is delayed, further deterioration in profitability is a concern.

2. Market sensitivity of core materials products: Titanium Oxide & Zinc Products (revenue -23.7%) and Resin Additives (revenue -12.8%) have been affected by lower volumes and prices and are highly sensitive to raw material and fuel prices and demand trends.

3. Accumulation of working capital: Accounts receivable of ¥228.9B and inventories of ¥169.3B indicate a substantial investment in working capital. If improvements in collections and inventory turnover are delayed, the increase in Operating Income may continue to have limited direct impact on improvements in Operating Cash Flow.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The operating margin is approximately in line with the industry median, while the net profit margin is below the industry median due to extraordinary losses (impairment).

Growth and Capital Efficiency

The revenue growth rate is significantly below the industry median, placing the Company at a relative disadvantage within an industry generally experiencing revenue growth.

※Source: Compiled by the Company

Key Points in the Financial Results

1. Despite a 3.5% YoY decline in revenue, Operating Income increased 14.7% YoY. The progress toward a higher-margin product mix centered on Electronic Materials, Catalysts, and Organic Chemicals is noteworthy as a structural improvement indicated by the financial results.

2. The 22.2% YoY decline in Net Income was primarily caused by the ¥24.3B impairment loss recorded in the Cosmetics Materials segment and should be viewed separately from the upward trend in Operating Income and Ordinary Income.

3. Progress against the full-year forecast exceeded the standard level for Operating Income, Ordinary Income, and Net Income, while revenue progress was somewhat delayed at 71.4%. Revenue trends in Q4 will be the key determinant of full-year results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥4,173–¥4,404 at ±1% in the cost of equity, and ¥4,263–¥4,301 at ±0.1 in ω.

Notes:

• Because progress of Net Income against the full-year forecast (97%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of forecast tend to exceed their forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Net Income has been substantially compressed relative to Operating Income due to the tax burden, acquisition-related expenses, and non-controlling interests, among other factors (Net Income ÷ Operating Income 46%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end have been used (there is a time lag between this figure and the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is neither a forecast of the market share price nor a recommendation for any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific stock. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, with consultation with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally resilient but statutory earnings were materially impaired by a large non-recurring charge. Nine-month revenue declined 3.5% year on year to ¥61.37bn. Operating income nevertheless increased 14.7% to ¥5.37bn. Ordinary income rose 10.2% to ¥5.48bn. The gross margin expanded 201bp year on year to 25.9%, as cost of sales declined 6.0% despite lower sales. The operating margin expanded 139bp to 8.7%, placing profitability within the stated 8-15% good benchmark range. SG&A was broadly flat at ¥10.56bn, rising only 0.2% year on year while gross profit increased 4.7%, demonstrating favorable operating leverage. Net income attributable to owners fell 22.2% to ¥2.90bn, and the net margin contracted 113bp to 4.7%. The principal cause was a ¥2.43bn impairment loss, concentrated in the cosmetics materials segment, partly offset by a ¥1.42bn gain on sale of fixed assets. Net extraordinary losses therefore totaled ¥1.14bn, reducing profit before tax to ¥4.34bn from ordinary income of ¥5.48bn. The effective tax rate was 31.4%, resulting in a tax burden of 0.668x and further limiting conversion of pre-tax profit into net income. Electron materials, the largest segment by operating-income contribution, was the principal earnings driver, while cosmetics materials moved into a loss. The balance sheet remains conservatively capitalized, with a 257.6% current ratio, 0.50x debt-to-equity ratio, and 43.63x interest coverage. However, cash declined 29.0% year on year to ¥11.49bn, while 67.9% of interest-bearing debt is short term and working-capital efficiency alerts remain material. Against full-year guidance, nine-month sales progress is 71.4% versus a standard 75%, whereas operating-income progress is 82.6% and net-income progress is 96.7%. This implies that the full-year operating target is attainable if margins hold, but the near-complete consumption of net-income guidance leaves limited room for further impairments or a weaker fourth quarter.

Profitability Analysis

Annualized DuPont ROE is 5.0%, comprising a 4.7% net profit margin, 0.697x asset turnover, and 1.50x financial leverage. The low ROE versus the 8% benchmark is primarily a profitability issue rather than an excessive-leverage issue: leverage is moderate and asset turnover is reasonable for a capital-intensive chemicals manufacturer, but the reported net margin is restrained by extraordinary losses. Operating profitability improved substantially, with gross margin rising to 25.9% from 23.9% and operating margin increasing to 8.7% from 7.4%. Cost of sales fell ¥2.91bn, or 6.0%, versus a ¥2.20bn revenue decline, while SG&A increased only ¥0.02bn; this is the key source of margin expansion. The five-factor decomposition shows an EBIT margin of 8.8%, tax burden of 0.668x, and interest burden of 0.808x. Interest coverage of 43.63x indicates that interest expense of ¥0.12bn is not a meaningful current constraint. The interest burden was instead affected mainly by the net extraordinary loss between EBIT and pre-tax income, rather than by financing costs alone. Electron materials is the core business, with revenue of ¥8.67bn, up 14.8% year on year, and segment profit of ¥1.44bn, up 25.0%; its 16.6% segment margin is the highest among the major profitable segments. Organic chemicals generated revenue of ¥5.43bn, up 17.4%, and segment profit of ¥0.71bn, up 45.1%, raising its margin to 13.0%. Other recorded revenue of ¥7.85bn, up 4.5%, and segment profit of ¥1.14bn, up 44.9%, for a 14.5% margin. Catalysts recorded revenue of ¥2.44bn, up 0.5%, and segment profit of ¥0.54bn, up 232.5%, lifting margin to 22.2% from 6.7%. In contrast, cosmetics materials revenue fell 37.8% to ¥1.12bn and segment profit deteriorated from a ¥0.11bn profit to a ¥0.22bn loss, compounded by the ¥2.41bn impairment. Titanium dioxide and zinc products revenue declined 23.7% to ¥7.64bn and profit fell 10.9% to ¥0.83bn, though its segment margin improved to 10.8%. Resin additives revenue declined 12.8% to ¥8.71bn and profit fell 25.2% to ¥0.80bn, compressing margin to 9.2%.

Growth Assessment

Revenue trends are mixed across the portfolio. Growth in electron materials, organic chemicals, contract processing, catalysts, and other businesses was insufficient to offset sharp declines in cosmetics materials, titanium dioxide and zinc products, and resin additives. Contract processing sales rose 4.1% to ¥4.99bn and operating profit increased 20.7% to ¥0.60bn. Hygiene materials sales declined 6.4% to ¥3.99bn and profit declined 1.9% to ¥0.31bn. Inorganic materials sales declined 1.4% to ¥3.95bn but profit increased 12.3% to ¥0.89bn. Medical business sales were stable at ¥6.58bn, while profit fell 19.9% to ¥0.16bn. Segment profit before corporate costs rose 10.7% to ¥7.20bn, while unallocated corporate costs were virtually unchanged at ¥1.83bn, supporting consolidated operating-income growth. Full-year guidance calls for revenue of ¥86.0bn, up 1.9%, operating income of ¥6.50bn, up 6.7%, and ordinary income of ¥6.50bn, up 3.5%. The annualized Q3 sales run rate is below the guided sales level, so a seasonal fourth-quarter revenue contribution is required. Conversely, Q3 operating income has already reached 82.6% of the full-year target, above the 75% standard progress rate by 7.6 percentage points. The stronger earnings progress reflects margin recovery rather than broad-based sales growth. Net income attributable to owners has reached 96.7% of the ¥3.00bn forecast, 21.7 percentage points above standard Q3 progress, despite the impairment charge. The outlook therefore depends on preserving improved gross margins, sustaining electron-materials and organic-chemical momentum, and avoiding renewed losses or asset charges in underperforming businesses.

Financial Health

Liquidity is strong on reported balance-sheet measures. Current assets of ¥65.42bn exceed current liabilities of ¥25.39bn, producing working capital of ¥40.02bn and a current ratio of 257.6%. The quick ratio is also robust at 190.9%, indicating that liquidity is not dependent on inventory liquidation. Total equity of ¥78.11bn funds 66.5% of total assets, while total liabilities represent 33.5% of assets. Interest-bearing debt is ¥15.58bn, equal to 0.50x equity, and debt-to-capital is 16.6%, both consistent with conservative solvency. Interest coverage of 43.63x supports ample debt-servicing capacity. The refinancing-risk alert remains relevant because short-term loans of ¥10.58bn account for 67.9% of interest-bearing debt, well above the 40% alert threshold. Cash of ¥11.49bn covers short-term loans by 1.09x, so cash alone presently covers the near-term bank-debt balance, while current assets provide a much larger secondary liquidity buffer. Cash and deposits nevertheless decreased ¥4.70bn, or 29.0%, year on year. Long-term loans declined ¥2.40bn, or 32.4%, to ¥5.01bn, indicating repayment or refinancing toward shorter maturities. Treasury stock increased in absolute deduction by ¥2.48bn to negative ¥4.18bn, consistent with capital returned through buybacks and a reduction in balance-sheet flexibility. A ¥3.00bn convertible bond with subscription rights is also recorded, which should be monitored alongside the stated interest-bearing debt metrics. Net defined benefit liability of ¥4.53bn is a material non-debt obligation relative to long-term liabilities and adds to fixed financial commitments. Goodwill is only ¥0.69bn, or 0.9% of equity and 0.6% of assets, so the balance sheet has limited dependence on acquired goodwill value.

Notable B/S Changes

Treasury stock: increased in absolute deduction by ¥2.48bn to negative ¥4.18bn (-145.9%) - indicates significant buyback activity and reduces equity flexibility. Long-term loans: decreased ¥2.40bn to ¥5.01bn (-32.4%) - lowers long-term debt but contributes to a debt structure in which 67.9% of interest-bearing debt is short term. Cash and deposits: decreased ¥4.70bn to ¥11.49bn (-29.0%) - liquidity remains strong, but the decline should be assessed against buybacks, debt maturities, and extended working-capital needs. Investment securities: increased ¥1.25bn to ¥6.37bn (+24.3%) - expands exposure to market-value movements and contributes to valuation differences in equity. Work in process: decreased ¥1.69bn to ¥3.17bn (-34.8%) - may reflect improved production flow or lower activity, while finished-goods inventory remains substantial at ¥16.93bn. Construction in progress: decreased ¥1.55bn to ¥3.49bn (-30.8%) - suggests completion or rationalization of capital projects.

Cash Flow Quality

The principal earnings-quality issue is the large non-recurring impact on reported net income. Extraordinary income was ¥1.42bn, entirely from gains on sale of fixed assets, while extraordinary losses were ¥2.56bn. The extraordinary losses included a ¥2.43bn impairment and ¥0.13bn loss on disposal or retirement of fixed assets. Net extraordinary losses of ¥1.14bn were equal to 39.3% of net income attributable to owners and the gross extraordinary items were 137.4% of net income, triggering the high-one-time-items alert. The impairment was overwhelmingly concentrated in cosmetics materials, where the segment reported a ¥0.22bn operating loss, linking the charge to a weakened business outlook rather than normal recurring operations. The ¥1.42bn asset-sale gain partly offsets the impairment in the current period but is similarly non-recurring. Accordingly, operating income and ordinary income provide a clearer indication of the period's recurring earning capacity than statutory net income. Working-capital quality warrants close attention: the high-receivable-days alert identifies DSO of 102 days, above both the 60-day alert threshold and the 45-day manufacturing efficiency benchmark. Accounts receivable were ¥22.89bn and electronically recorded monetary claims were ¥4.79bn, representing a substantial investment in customer credit. The high-inventory-days alert identifies DIO of 152 days, and a second inventory-days alert identifies 102 days; both readings are above their respective 90-day and 60-day thresholds. Finished goods were ¥16.93bn, raw materials ¥5.20bn, and work in process ¥3.17bn, illustrating substantial inventory tied to manufacturing and demand conditions. The long cash-conversion-cycle alert of 205 days exceeds the 120-day warning threshold, increasing exposure to demand volatility, commodity-price moves, inventory obsolescence, and collections discipline. These working-capital indicators make conversion of accounting earnings into cash an important monitoring priority.

Dividend Sustainability

The declared Q2 dividend is ¥65 per share. Relative to nine-month EPS of ¥184.88, the disclosed calculated payout ratio is 38.1%, indicating that the interim distribution is covered by cumulative earnings. Full-year guidance calls for DPS of ¥145 and EPS of ¥191.20, implying a forecast dividend payout ratio of 75.8%. This exceeds the 60% sustainability benchmark but remains below 100%, so the dividend is earnings-covered under company guidance. The implied year-end dividend is ¥80 per share after the ¥65 interim payment. The forecast payout leaves a narrower retention buffer than the Q3 cumulative ratio suggests, particularly because reported net income includes a large impairment charge and has already reached 96.7% of the full-year target. The increase in treasury-stock deduction by ¥2.48bn indicates that buybacks have also been a meaningful capital-allocation item; dividends plus buybacks should therefore be assessed as a total return ratio rather than interpreting the dividend payout ratio in isolation. Strong liquidity, low reported debt-to-capital, and substantial equity provide balance-sheet capacity for shareholder distributions. Continued dividend sustainability will depend principally on achieving the ¥3.00bn full-year net-income forecast, maintaining operating-margin recovery, and containing cash tied up in receivables and inventory.

Risk Assessment

Business risks include Demand and product-mix risk: consolidated revenue fell 3.5%, with cosmetics materials down 37.8%, titanium dioxide and zinc products down 23.7%, and resin additives down 12.8%., Cosmetics-materials restructuring risk: the segment posted a ¥0.22bn operating loss and a ¥2.41bn impairment, creating execution risk around restoring asset utilization and profitability., Chemical-manufacturing inventory risk: inventory-days alerts of 152 days and 102 days both exceed relevant warning thresholds, raising exposure to slow-moving stock, obsolescence, and price declines., Customer-credit and collection risk: the DSO alert of 102 days is above the 60-day threshold, and receivables plus electronic claims totaled ¥27.68bn., Industry-specific risk: titanium dioxide, zinc, resin additives, and inorganic chemical businesses are exposed to cyclical industrial demand, feedstock and energy costs, price competition, and environmental compliance requirements., Portfolio concentration risk: electron materials is the largest contributor to segment profit at ¥1.44bn, making the improved consolidated margin increasingly dependent on continued performance in that business..

Financial risks include Refinancing risk: 67.9% of interest-bearing debt is short term, exceeding the 40% alert threshold, although cash covers short-term loans by 1.09x and the current ratio is 257.6%., Cash-balance risk: cash and deposits fell 29.0% year on year to ¥11.49bn, reducing the immediate liquidity cushion despite strong current-asset coverage., Capital-return risk: treasury stock increased in absolute deduction by ¥2.48bn while the forecast dividend payout ratio is 75.8%, which reduces retained capital if earnings weaken., Pension-obligation risk: net defined benefit liability was ¥4.53bn, a fixed long-term obligation that should be considered alongside borrowings..

Key concerns include High one-time items: gross extraordinary items equal 137.4% of net income; the root cause is the ¥2.43bn impairment and ¥1.42bn fixed-asset sale gain. The impact is that statutory earnings are volatile and less representative of recurring profitability., High receivable days: DSO of 102 days indicates slow conversion of sales into cash. This raises working-capital funding needs and heightens sensitivity to customer-credit deterioration., High inventory days: alerts of 152 days and 102 days both point to inventory significantly above manufacturing efficiency benchmarks. The impact is elevated obsolescence, write-down, and future cash-release risk., Long cash conversion cycle: 205 days is above the 120-day warning level. The combination of high receivables and inventory can constrain cash generation even as operating margins improve., Refinancing risk: the short-term debt ratio of 67.9% reflects a maturity concentration. Strong liquidity moderates near-term risk, but renewal terms and funding costs remain important..

Investment Implications

Key takeaways include Recurring operating performance improved: operating income rose 14.7% and operating margin expanded 139bp to 8.7% despite a 3.5% revenue decline., Electron materials is the core earnings engine, delivering ¥1.44bn of segment profit and a 16.6% margin., Reported net income understates operating momentum because a ¥2.43bn impairment and other extraordinary items produced a net extraordinary loss of ¥1.14bn., The company has strong reported liquidity and conservative leverage, but falling cash, short debt maturities, and extended working-capital metrics require monitoring., Full-year operating-income guidance appears within reach at 82.6% Q3 progress, while sales require a comparatively stronger fourth quarter and net-income guidance offers limited downside buffer..

Metrics to watch include Electron materials revenue growth and segment margin, Cosmetics materials recovery, asset utilization, and any incremental impairment, Titanium dioxide and zinc products revenue and pricing trajectory, DSO of 102 days, inventory-days alerts of 152 days and 102 days, and the 205-day cash conversion cycle, Cash and deposits relative to short-term loans and the 67.9% short-term debt ratio, Fourth-quarter revenue required to meet ¥86.0bn full-year guidance, Full-year EPS relative to ¥191.20 guidance and DPS relative to the ¥145 forecast.

Regarding relative positioning, The company combines a sound balance sheet and good operating-margin recovery with below-benchmark annualized ROE of 5.0%. Its core electron-materials profitability compares favorably with more cyclical commodity-oriented chemical operations, but portfolio performance remains uneven and working-capital intensity is materially weaker than standard manufacturing efficiency benchmarks.